Biometrics

Biometrics Optimization Solution (B.O.S)

Responding to ICH GCP E6(R2) and Oversight Requirements

Starting with a complete biometrics GAP analysis, to determine what steps to take to plan and implement your optimal data oversight strategy, we will work with you to develop a customized approach including processes, system selection and deployment and consistent data strategies.

As your partner, we’ll leverage our indication-specific experience to guide you through the full data management process, including:
  • Guaranteed ICH E6 (R2) Compliance
  • Integrated Risk Management Analysis & Mitigation
  • Improved Control of Data Acquisition, Storage & Reporting
  • All supported by a complete governance package to prove effective oversight and risk management

Why use B.O.S.?

Oversight is a requirement of the ICH E6(R2) addendum, according to which the ultimate responsibility for the quality and integrity of the trial data resides with the sponsor. This requires a risk-based approach to quality management and oversight. Conducting clinical data oversight can be challenging, particularly for companies that lack functional experts internally.

There are several ways to mitigate risks with an outsourcing model; using an experienced team through B.O.S. is both complete and cost-effective.

Why choose Alira Health?

The CROS NT and Alira Health biometrics team has provided expert statistical guidance for over 500 projects, including regulatory communication and submissions, study-based data management, biostatistics, and statistical programming. You will benefit from our:

  • Exceptional customer service and site relations
  • In-depth expertise across the entire clinical trial process
  • Flexible and tailored service delivered by multidisciplinary and global teams
  • Frequent, transparent, and professional communication
  • Guarantee we will lead your study efficiently, safely, and successfully

Related News

Multimedia May 19, 2022
Fireside Chat Replay: Latest Developments in Oncology Supportive Care
In this fireside chat, we sit down with two medical experts in oncology and discuss some of the fascinating developments that are happening in the oncology supportive care field.
Clinical
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Multimedia April 15, 2022
Alira Health’s Transformation Talks: Real-World Evidence Strategy Playbook
As a special guest, our episode “Real-World Evidence Strategy Playbook” with Romain Finas, Vice President of Real-World Evidence at Alira Health, is now live! Listen to this podcast(...)
Clinical RWE
Multimedia April 13, 2022
Fireside Chat Replay: Clinical Trials in Rare Disease: Best Practices for Integrating the Patient Voice
This webinar will focus on the U.S. FDA and EU MDR/IVDR regulatory pathways and strategies for medical device startups based in the Asia Pacific.
Clinical Patient Engagement
Events April 12, 2022
SCOPE Europe 2022
We are thrilled to announce that this year we will be joining the 4th Annual Summit for Clinical Trials Operations Executives Europe (SCOPE Europe).
Clinical
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.